Stay updated on Pembrolizumab for Rare Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Rare Tumors Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-02T12:14:20.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition-related updates and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-26T11:38:27.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T12:22:46.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:10:15.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Access to the study record is blocked by a 403 Forbidden error, replacing the usual study details with an error page. The surrounding site chrome remains but the main content is not accessible.
    Difference
    21%
    Check dated 2026-09-21T20:53:20.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6 instead of Revision: v3.6.5, indicating a software update. The study content and layout remain unchanged.
    Difference
    0.0%
    Check dated 2026-08-31T16:54:43.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Rare Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Rare Tumors Clinical Trial page.